Eli Lilly and Company $LLY Shares Sold by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management LLC has reduced its stake in Eli Lilly and Company by 55.6%, now holding 600 shares valued at approximately $496,000.
• In contrast, PNC Financial Services Group Inc. increased its stake by 97.5%, and Vanguard Group Inc. raised its holdings by 6.7% during the same period.
• Eli Lilly recently reported $6.31 earnings per share, exceeding analysts' estimates, and announced a quarterly dividend of $1.50 per share, reflecting a yield of 0.8%.

ADAR1 Capital Management LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 55.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600 shares of the company's stock after selling 750 shares during the period. ADAR1 Capital Management LLC's holdings in Eli Lilly and Company were worth $496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC grew its holdings in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $40,000. Finally, Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $43,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY traded up $4.39 during trading on Thursday, reaching $742.22. 2,419,935 shares of the company's stock were exchanged, compared to its average volume of 4,141,353. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $943.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $702.48 billion, a P/E ratio of 48.51, a price-to-earnings-growth ratio of 1.02 and a beta of 0.47. The company's fifty day simple moving average is $745.91 and its 200-day simple moving average is $783.42.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm posted $3.92 EPS. Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent analyst reports. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Guggenheim lowered their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.